Natera, Inc. (NASDAQ: NTRA) is a global biotechnology company specializing in advanced genetic testing and diagnostics. Since its founding in 2004 and headquartered in San Carlos, California, Natera has leveraged proprietary molecular biology and bioinformatics platforms to develop noninvasive tests that address critical needs in women’s health, oncology and organ health. The company serves hospitals, physician practices and reference laboratories with testing services designed to improve clinical decision-making and patient outcomes.
In women’s health, Natera’s flagship Panorama™ noninvasive prenatal test (NIPT) screens for common fetal chromosomal conditions as early as ten weeks into pregnancy. The company also offers Horizon™ carrier screening, which evaluates inherited conditions that could be passed to offspring. These solutions are supported by a network of genetic counselors and local laboratories in key markets, including the United States and Europe, enabling rapid turnaround and personalized patient support.
Oncology testing is anchored by Signatera™, a personalized, tumor-informed circulating tumor DNA (ctDNA) assay that monitors minimal residual disease, assesses treatment response and detects recurrence across multiple cancer types. Signatera’s bespoke approach begins with sequencing a patient’s tumor tissue and blood to design individualized assays, allowing clinicians to track disease dynamics with high sensitivity throughout a patient’s treatment journey.
In the organ health space, Natera offers Prospera™, a donor-derived cell-free DNA test that provides early detection of transplant rejection in kidney, heart and lung recipients. Combined with comprehensive reporting and expert support, Prospera helps transplant teams make timely interventions. Under the leadership of co-founders and senior management with deep experience in molecular diagnostics, Natera continues to expand its global footprint and invest in research collaborations to broaden the clinical applications of its cell-free DNA testing platform.
AI Generated. May Contain Errors.
